The global market for Interventional Oncology Devices was estimated at US$2.6 Billion in 2023 and is projected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Interventional Oncology Devices Market - Key Trends and Drivers Summarized
How Are Interventional Oncology Devices Advancing Cancer Treatment?
Interventional oncology devices are revolutionizing cancer treatment by offering minimally invasive procedures that target tumors with precision, reducing the need for traditional surgery and minimizing damage to surrounding tissues. These devices are used in image-guided procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), and transarterial chemoembolization (TACE), which deliver targeted therapies directly to tumors. Interventional oncology treatments are increasingly being adopted for liver, lung, kidney, and bone cancers, providing patients with safer, less invasive alternatives to open surgery. These technologies are improving survival rates, reducing recovery times, and offering new hope to patients who may not be candidates for traditional surgery.What Technological Innovations Are Driving Interventional Oncology?
Technological advancements in imaging modalities, robotics, and ablation techniques are driving the growth of interventional oncology. Innovations in imaging technologies, such as MRI, CT, and ultrasound, are enabling real-time, high-resolution visualization of tumors during procedures, improving the accuracy and safety of treatments. Robotic systems are enhancing the precision of interventions, allowing for better targeting of tumors in hard-to-reach areas. New ablation techniques, including microwave ablation and cryoablation, are providing more effective options for tumor destruction while minimizing damage to healthy tissues. These advancements are expanding the capabilities of interventional oncology and allowing for the treatment of a broader range of cancers.How Do Market Segments Define the Growth of Interventional Oncology Devices?
Device types include ablation devices, embolization devices, and support devices, with ablation devices leading the market due to their widespread use in minimally invasive tumor destruction. Procedures include radiofrequency ablation, microwave ablation, and transarterial chemoembolization, with microwave ablation gaining popularity due to its higher efficacy in treating larger tumors. Cancer types treated with interventional oncology devices include liver, lung, kidney, and bone cancers, with liver cancer being the largest segment due to the high prevalence of hepatocellular carcinoma. The market is growing significantly in regions such as North America and Europe, driven by the availability of advanced healthcare infrastructure and the increasing adoption of minimally invasive treatments.What Factors Are Driving the Growth in the Interventional Oncology Devices Market?
The growth in the interventional oncology devices market is driven by several factors, including the increasing incidence of cancer, the growing preference for minimally invasive treatments, and advancements in imaging and ablation technologies. As cancer rates rise globally, demand for less invasive and more targeted treatment options is increasing. Interventional oncology offers a solution by providing procedures that are less traumatic for patients and offer faster recovery times. Technological innovations in real-time imaging and precision ablation are further driving market growth by improving the effectiveness and safety of these treatments. Additionally, the rising adoption of interventional oncology in emerging markets, driven by improving healthcare infrastructure and access to advanced medical technologies, is contributing to the expansion of the market.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Embolization Devices segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 7.1%. The Ablation Devices segment is also set to grow at 5.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $675.9 Million in 2023, and China, forecasted to grow at an impressive 9.5% CAGR to reach $915.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Interventional Oncology Devices Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Interventional Oncology Devices Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Interventional Oncology Devices Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Interventional Oncology Devices market such as AngioDynamics, Inc., Boston Scientific Corporation, BTG plc, C. R. Bard, Inc., Cook Medical LLC and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Interventional Oncology Devices market report include:
- AngioDynamics, Inc.
- Boston Scientific Corporation
- BTG plc
- C. R. Bard, Inc.
- Cook Medical LLC
- EDAP TMS S.A.
- Healthtronics, Inc.
- IMBiotechnologies Ltd.
- Medtronic plc
- Merit Medical Systems, Inc.
- Neuwave Medical, Inc.
- Profound Medical Corp.
- Sirtex Medical Limited
- Teleflex Incorporated
- Terumo Corporation
- Trod Medical
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AngioDynamics, Inc.
- Boston Scientific Corporation
- BTG plc
- C. R. Bard, Inc.
- Cook Medical LLC
- EDAP TMS S.A.
- Healthtronics, Inc.
- IMBiotechnologies Ltd.
- Medtronic plc
- Merit Medical Systems, Inc.
- Neuwave Medical, Inc.
- Profound Medical Corp.
- Sirtex Medical Limited
- Teleflex Incorporated
- Terumo Corporation
- Trod Medical
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 92 |
Published | November 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 2.6 Billion |
Forecasted Market Value ( USD | $ 3.9 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |